The European Commission is poised to agree a groundbreaking €2bn partnership with the pharmaceutical industry this week designed to win back Europe’s place as a centre for global medical innovation.

The Innovative Medicines Initiative (IMI), financed equally by industry and the Commission, will support research by academic and industry groups over seven years designed to speed up the predictable testing of safety and efficacy of new medicines.